Navigation Links
Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum
Date:9/5/2008

the diagnosis and treatment of disease, and the timing of launch of the first diagnostic tests applying Rosetta's microRNA technology constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover and develop novel diagnostics and therapeutic tools, which is unproven and may never lead to marketable products or services; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; Rosetta's ability to obtain, maintain and protect the intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta's ability to successfully develop its candidate tools, products and services, all of which are in early stages of development; Rosetta's ability to obtain regulatory clearances or approvals that may be required for its products and services; the ability to obtain coverage and adequate payment from health insurers for the products and services comprising Rosetta's technology; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of the date o
'/>"/>
SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. M. D. Anderson to Initiate Clinical Validation Study on Rosetta Genomics MicroRNA-based Diagnostic Assay Identifying the Origin of Cancer Metastases
2. First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology Receives Regulatory Approval
3. Rosetta Genomics and Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary and Metastatic Tumors in the Brain
4. Rosetta Genomics and Rabin Medical Center Announce a Collaboration Focused on MicroRNA-Based Diagnostics
5. Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer
6. Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
8. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
9. Orion Genomics Gains Exclusive Worldwide Rights to the IGF2 Gene for Colorectal Cancer Risk Testing Through Licensing Agreement With Johns Hopkins University
10. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
11. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... , May 26, 2015  AbbVie (NYSE: ... Phase 3 GIFT-I study of its investigational, all-oral, ... treatment with ombitasvir/paritaprevir/ritonavir at the Annual Meeting of ... Japan . 1 GIFT-I evaluated ... infected Japanese patients, with and without cirrhosis, who ...
(Date:5/26/2015)... -- Thoratec Corporation (NASDAQ: THOR ), a world ... and restore failing hearts, said today it will participate ... Conference on Tuesday, June 9. D. ... provide an update on the company, beginning at 2:00 ... The presentation will be available through the ...
(Date:5/26/2015)... , May 26, 2015  Amgen (NASDAQ: AMGN ... the Phase 3 OPTiM study in the Journal ... The data published in JCO , which were ... Society of Clinical Oncology (ASCO) in 2013 and 2014, ... patients with unresected stage IIIB, IIIC or IV metastatic ...
Breaking Medicine Technology:AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 2AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 3AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 4AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 5AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 6Thoratec Presentation At Goldman Sachs Healthcare Conference To Be Webcast 2Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 2Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 3Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 4Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 5Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 6Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 7Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 8
(Date:5/26/2015)... New York (PRWEB) May 26, 2015 ... ( http://www.xareltolawsuit2015.com/ ) filed on behalf of individuals who ... for the litigation’s June 11th Science Day. According to ... District of Louisiana, on May 21st, topics to be ... the drug, the use of blood test based testing ...
(Date:5/26/2015)... 26, 2015 Now offering innovative, safe, ... center of Dr. Hedi Belajouza in Tunisia ... , Perfection to the last detail — meticulous hair ... location of the harvested follicle — are all results ... predominantly visible in the artistry and talent of Tunisian ...
(Date:5/26/2015)... San Francisco, CA (PRWEB) May 26, 2015 ... interested students to join them for the Open House/Free Application ... 11 a.m. and go until 4 p.m. and will be ... in San Francisco, CA. , After checking in, attendees will ... will then be a tour of the campus at 11:45 ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 Marching ... the summer season, and thanks to the efforts ... solutions, more of their musicians are protecting their ... With over 400 participating groups, Etymotic’s Adopt-a-Band program ... by Etymotic are now for sale in drum ...
(Date:5/26/2015)... 3,000 senior industry executives are expected at the ... of the connected car. A very special attraction for ... read a driver’s brain waves. Visitors to its booth ... mind alone just by gripping the steering wheel! , ... working on cognitive load, altering music based on the ...
Breaking Medicine News(10 mins):Health News:Federal Xarelto Lawsuits Move Forward, as Court Establishes Procedures for Upcoming Science Day 2Health News:Federal Xarelto Lawsuits Move Forward, as Court Establishes Procedures for Upcoming Science Day 3Health News:Federal Xarelto Lawsuits Move Forward, as Court Establishes Procedures for Upcoming Science Day 4Health News:Hair Transplant Center in Tunisia Now Offering Innovative Restoration Technology 2Health News:Hair Transplant Center in Tunisia Now Offering Innovative Restoration Technology 3Health News:Hair Transplant Center in Tunisia Now Offering Innovative Restoration Technology 4Health News:ACTCM to Host Summer Open House 2Health News:Marching Musicians Getting In Step With Hearing Protection 2Health News:The World’s Biggest Connected Car Exhibition is Back in Detroit 2Health News:The World’s Biggest Connected Car Exhibition is Back in Detroit 3
... , , BIRMINGHAM, Ala., Sept. 21 ... that it has been awarded a $77.2 million contract modification by ... Phase 3 development of its influenza neuraminidase inhibitor, intravenous (i.v.) peramivir, ... "We are very excited to continue working with the ...
... , BOSTON, Sept. 21 SmarterTravel(R), a comprehensive ... for staying safe while traveling during this highly anticipated flu season. , ... Check your health insurance: Before you depart, ... case you develop the swine flu, or any illness, while traveling. , ...
... ... New England Office and Offers Assistance to 3 Local Companies , ... (Vocus) -- Omnion Consulting ... even subsisting, is offering 1 day (8 hours) of free strategic consulting to 3 ...
... collection of fluid around the heart, typically occurs in ... an invasive surgical drainage technique. However researchers have discovered ... is just as effective requiring no ... cost savings over the surgical drainage technique, according to ...
... , Second Annual Event Promotes Adaptive ... Sept. 20 Secretary of Veterans Affairs Eric K. Shinseki offered encouragement ... the 2nd National Veterans Summer Sports Clinic in San Diego. Calling ... kicked-off the clinic by telling his personal story of dealing with a ...
... toxic for some: study , SUNDAY, Sept. 20 ... women with advanced ovarian cancer, Japanese researchers say. ... weeks is considered standard first-line chemotherapy for advanced ... paclitaxel is seen as a way to increase ...
Cached Medicine News:Health News:BioCryst Awarded Additional $77.2 Million by the U.S. Department of Health & Human Services To Develop Peramivir for Influenza 2Health News:BioCryst Awarded Additional $77.2 Million by the U.S. Department of Health & Human Services To Develop Peramivir for Influenza 3Health News:BioCryst Awarded Additional $77.2 Million by the U.S. Department of Health & Human Services To Develop Peramivir for Influenza 4Health News:BioCryst Awarded Additional $77.2 Million by the U.S. Department of Health & Human Services To Develop Peramivir for Influenza 5Health News:Travel Precautions Critical During Swine Flu Season 2Health News:Travel Precautions Critical During Swine Flu Season 3Health News:New England Business Offers Free Service to Companies in Need 2Health News:Secretary Shinseki Kicks-Off National Sports Clinic 2Health News:New Chemo Regimen May Benefit Ovarian Cancer Patients 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: